X-BODY, Jiangsu Hengrui To Develop Novel Therapeutic Antibodies
April 15, 2013
X-BODY Biosciences has signed an agreement with Jiangsu Hengrui to commercialize therapeutic antibodies for age-related macular degeneration.
AsianScientist (Apr. 15, 2013) – X-BODY Biosciences has signed an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd., in which Hengrui will develop and commercialize novel therapeutic antibodies for age-related macular degeneration (AMD) in China, Taiwan, Macao, and Hong Kong.
Under the terms of the collaboration, Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts, for the Greater China markets. X-BODY retains all development and commercialization rights outside of Greater China.
Detailed financial terms were not disclosed, but terms of the alliance include an upfront payment; clinical, regulatory and commercialization milestones; and royalties on revenues from commercialized products.
“It is an important part of our corporate strategy to partner with biotechs around the world that could provide interesting molecules for us to develop and commercialize, and we are excited to take on board the first of hopefully many development programs from X-BODY,” said Lianshan Zhang, Ph.D., President of Global R&D, Jiangsu Hengrui Medicine Co., Ltd.
“This collaboration with Hengrui, the clear leader in pharmaceutical development in China, is an important step on our path to validate the capabilities of our DNA Display drug discovery platform. We are encouraged to see our platform yield antibodies that could have a meaningful impact on patients’ lives, especially for a disease as life-altering as AMD,” added Julius Knowles, CEO of X-BODY.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.